Kim YN, Joung JG, Park E, Kim JW, et al. Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045". Int J Cancer 2023 Oct 31. doi: 10.1002/ijc.34786.
PMID: 37907776